In short
Clinical trials investigating Valsartan are studying how it may help in different heart and blood vessel conditions, and in some studies how it compares with other treatments. These trials look at safety, effectiveness, and clinical outcomes in groups such as people with heart failure, cardiomyopathy, diabetes, children and young adults with Marfan syndrome, and kidney transplant recipients.
Key points
- Clinical trials investigating Valsartan are focused on several patient groups, especially people with heart failure, cardiomyopathy, diabetes, Marfan syndrome, and kidney transplant problems. The studies include early Phase 1 bioequivalence trials in healthy volunteers and larger Phase 3 trials in patients. Main goals include checking heart function, heart failure relapse, aortic root growth, kidney function, and other clinical outcomes. Some trials compare Valsartan with other drugs, while others study it as part of sacubitril/valsartan. The target populations vary from children and young adults with Marfan syndrome to adults with heart failure or transplant-related kidney concerns.
Clinical trials overview
The trial data shows that Valsartan is being studied in a wide range of clinical settings, mostly in heart disease and blood vessel disease. These studies include both direct Valsartan trials and trials where Valsartan is part of a combination treatment such as sacubitril/valsartan.
The studies are in different stages, including Phase 1, Phase 2, and Phase 3, plus some low-intervention trials. This means the research ranges from early testing in healthy volunteers to larger patient studies that measure real health outcomes.
Heart failure and related heart studies
Most of the listed trials focus on heart failure, which is when the heart does not pump blood as well as it should. Several studies look at whether Valsartan, alone or in combination, can help prevent worsening heart function or reduce later heart failure events.
One authorised Phase 3 study in people with diabetes mellitus type 2 is testing whether high-dose treatment with RAS-antagonists and beta-blockers can reduce cardiac death or cardiac hospitalisation. Valsartan 320 mg is one of the study drugs, and the trial uses a combined endpoint based on the first cardiac death or cardiac hospitalisation.
Another Phase 2 heart failure study is testing XXB750 in symptomatic patients with LVEF below 50%, while patients receive standard care that may include ACE inhibitors, ARBs, or sacubitril/valsartan. The main outcome is the change in log NT-proBNP from baseline to Week 16.
A Phase 3 study in ischemic heart failure with mid-range ejection fraction compares sacubitril/valsartan with ramipril and measures the change in left ventricular end-systolic volume after 12 months by MRI. This helps researchers see whether treatment changes heart size and shape over time.
Another authorised Phase 3 study looks at pharmacological optimisation in heart failure and includes Valsartan among many treatment options. It has both a retrospective part, which studies current prescribing patterns and sex differences, and a prospective part, which measures mortality, heart failure readmission, quality of life, adherence, and side effects.
Several other heart failure trials study withdrawal, continuation, or timing of treatment in patients who improved after cardiac resynchronisation therapy or who have recovered left ventricular function. In these studies, Valsartan appears in the treatment lists, and the main concern is whether stopping or changing therapy leads to relapse of cardiomyopathy or heart failure.
One completed Phase 3 trial compared sacubitril/valsartan with enalapril in patients with heart failure with reduced ejection fraction and pulmonary hypertension. The main outcomes were changes in mean pulmonary artery pressure and pulmonary vascular resistance, which are measures of pressure and resistance in the lung circulation.
Another completed Phase 3 trial in heart failure with preserved ejection fraction and secondary mitral valve regurgitation studied sacubitril/valsartan and measured the slope of mPAP/CO during exercise testing. Secondary outcomes included valve measurements and quality of life.
There is also an authorised Phase 3 trial in heart failure with recovered ejection fraction that studies whether stopping beta-blockers is non-inferior to continuing them. Valsartan appears in the intervention list, and the primary endpoint is a composite of heart failure relapse and other adverse cardiovascular outcomes during follow-up.
Marfan syndrome and aortic disease
One authorised Phase 3 trial studies Marfan syndrome and related inherited aortic diseases in children and young adults. The goal is to see whether Valsartan can slow the widening of the aortic root, which is the first part of the aorta coming out of the heart.
The primary outcome in this study is the annual change in aortic diameter measured by transthoracic echocardiography, which is an ultrasound scan of the heart. This is a direct way to track whether the aorta grows more slowly over time.
Another Phase 3 trial in arrhythmogenic cardiomyopathy studies sacubitril/valsartan and looks at left ventricular fibrosis, left ventricular ejection fraction, and ventricular arrhythmia burden. Although this study uses the combination treatment, it still belongs to the wider group of Valsartan-related trials in the dataset.
Kidney transplant study
One authorised Phase 3 study is in renal transplant patients with signs of post-transplant glomerulopathy. It tests whether Valsartan can help prevent a drop in glomerular filtration, which is a measure of kidney filtering function.
This trial does not list a primary endpoint in the source data, but its brief summary makes the research aim clear: to see whether an ARB can help protect kidney function in a specific transplant subgroup with urinary PECs.
Healthy volunteer bioequivalence studies
Two completed Phase 1 studies enrolled healthy volunteers to compare two formulations of sacubitril/valsartan. These studies were designed to show bioequivalence, meaning the test product and reference product behave similarly in the body.
The main outcomes were sacubitril and Valsartan blood exposure measures, including AUC0-t and Cmax. These measures help researchers compare how much medicine gets into the blood and how high the blood level becomes after dosing.
Main endpoints used in the trials
The trials use many different endpoints, but several are repeated across studies. Common heart outcomes include changes in left ventricular ejection fraction, left ventricular volume, heart failure relapse, and hospitalisation for heart failure or cardiac causes.
Some studies focus on blood markers such as NT-proBNP, which can reflect how much strain is placed on the heart. Others use imaging tests like MRI, echocardiography, or stress testing to measure heart structure and function more directly.
In the Marfan study, the main endpoint is the yearly change in aortic diameter. In the kidney transplant study, the goal is to protect glomerular filtration. In the bioequivalence studies, the main endpoints are AUC and Cmax for sacubitril and Valsartan.
Who can participate
Participation depends on the study question. The trials include healthy volunteers, adults with heart failure, people with diabetes and no known heart disease, patients with cardiomyopathy, children and young adults with Marfan-related disease, and kidney transplant recipients.
Some studies are looking for people with recovered heart function, while others focus on patients with active symptoms or special heart conditions such as pulmonary hypertension or mitral valve regurgitation. This shows that Valsartan-related research is aimed at very different patient groups, not just one disease.